Table 4 Treatment group differences in corpus callosum NODDI ODI at follow-up evaluation
Median; mean (SD) {n} | Placebo | Choline | Statistic | Significance | Effect size |
|---|---|---|---|---|---|
Rostrum | 0.11; 0.11 (0.02) {9} | 0.10; 0.11 (0.02) {9} | W = 29.0 | 0.34 | 0 |
Genu | 0.13; 0.13 (0.03) {9} | 0.13; 0.12 (0.02) {9} | W = 33.0 | 0.55 | −0.39 |
Body prefrontal | 0.13; 0.13 (0.02) {9} | 0.14; 0.13 (0.02) {9} | W = 46.0 | 0.67 | 0 |
Body premotor | 0.11; 0.12 (0.03) {9} | 0.12; 0.12 (0.04) {9} | W = 34.0 | 0.61 | 0 |
Body central | 0.12; 0.12 (0.02) {9} | 0.10; 0.11 (0.01) {9} | W = 21.0 | 0.09 | −0.13 |
Body parietal | 0.13; 0.14 (0.03) {9} | 0.12; 0.12 (0.01) {9} | W = 18.0 | 0.05 | −0.21 |
Body temporal | 0.14; 0.15 (0.02) {9} | 0.14; 0.14 (0.01) {9} | W = 30.0 | 0.39 | −0.63 |
Splenium | 0.11; 0.11 (0.01) {9} | 0.09; 0.09 (0.02) {9} | W = 15.0 | 0.02* | −1.26 |